FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294307521> ?p ?o ?g. }

• W4294307521 endingPage "791" @default.
• W4294307521 startingPage "781" @default.
• W4294307521 abstract "Approximately half of patients with high-risk HER2-positive early-stage breast cancer (ESBC) do not have pathologic complete response (pCR) after neoadjuvant therapy. The residual burden of disease among this population has not been previously quantified.We used decision-modeling techniques to simulate recurrence, progression from locoregional to distant cancer, breast cancer-related mortality, and mortality from other causes over a 10-year period in a hypothetical cohort. We derived progression probabilities primarily from the KATHERINE trial of T-DM1 (ado-trastuzumab emtansine) and mortality outcomes from the published literature. Modeled outcomes included recurrences, breast cancer deaths, deaths from other causes, direct medical costs, and costs due to lost productivity. To estimate the residual disease burden, we compared outcomes from a cohort of patients treated with T-DM1 versus a hypothetical cohort with no disease recurrence.We estimated that 9,300 people would experience incident high-risk HER2-positive ESBC in the United States in 2021 based on cancer surveillance databases, clinical trial data, and expert opinion. We estimated that, in this group, 2,118 would experience disease recurrence, including 1,576 distant recurrences, and 1,358 would experience breast cancer deaths. This residual disease burden resulted in 6,435 life-years lost versus the recurrence-free cohort, and healthcare-related costs totaling $644 million, primarily associated with treating distant cancers.Patients with HER2-positive ESBC who do not achieve pCR after neoadjuvant therapy are at ongoing risk of recurrence despite the effectiveness of neoadjuvant treatment. There is substantial clinical and economic value in further reducing the residual disease burden in this population." @default.
• W4294307521 created "2022-09-02" @default.
• W4294307521 creator A5012218557 @default.
• W4294307521 creator A5017550097 @default.
• W4294307521 creator A5041075056 @default.
• W4294307521 creator A5052256740 @default.
• W4294307521 creator A5067278845 @default.
• W4294307521 creator A5072015843 @default.
• W4294307521 creator A5085042140 @default.
• W4294307521 date "2022-12-01" @default.
• W4294307521 modified "2023-10-14" @default.
• W4294307521 title "Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model" @default.
• W4294307521 cites W1983930571 @default.
• W4294307521 cites W2019458473 @default.
• W4294307521 cites W2075894019 @default.
• W4294307521 cites W2096552494 @default.
• W4294307521 cites W2109924789 @default.
• W4294307521 cites W2162982444 @default.
• W4294307521 cites W2167976870 @default.
• W4294307521 cites W2519603001 @default.
• W4294307521 cites W2588881638 @default.
• W4294307521 cites W2768649895 @default.
• W4294307521 cites W2803984949 @default.
• W4294307521 cites W2810718681 @default.
• W4294307521 cites W2902218997 @default.
• W4294307521 cites W2921099093 @default.
• W4294307521 cites W3006134372 @default.
• W4294307521 cites W3012380787 @default.
• W4294307521 cites W3110093044 @default.
• W4294307521 cites W3126013715 @default.
• W4294307521 cites W3165078374 @default.
• W4294307521 cites W3188251561 @default.
• W4294307521 cites W4205724345 @default.
• W4294307521 doi "https://doi.org/10.1016/j.clbc.2022.08.012" @default.
• W4294307521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36220724" @default.
• W4294307521 hasPublicationYear "2022" @default.
• W4294307521 type Work @default.
• W4294307521 citedByCount "1" @default.
• W4294307521 countsByYear W42943075212023 @default.
• W4294307521 crossrefType "journal-article" @default.
• W4294307521 hasAuthorship W4294307521A5012218557 @default.
• W4294307521 hasAuthorship W4294307521A5017550097 @default.
• W4294307521 hasAuthorship W4294307521A5041075056 @default.
• W4294307521 hasAuthorship W4294307521A5052256740 @default.
• W4294307521 hasAuthorship W4294307521A5067278845 @default.
• W4294307521 hasAuthorship W4294307521A5072015843 @default.
• W4294307521 hasAuthorship W4294307521A5085042140 @default.
• W4294307521 hasBestOaLocation W42943075211 @default.
• W4294307521 hasConcept C121608353 @default.
• W4294307521 hasConcept C126322002 @default.
• W4294307521 hasConcept C143998085 @default.
• W4294307521 hasConcept C146357865 @default.
• W4294307521 hasConcept C151730666 @default.
• W4294307521 hasConcept C201903717 @default.
• W4294307521 hasConcept C2778292576 @default.
• W4294307521 hasConcept C2779134260 @default.
• W4294307521 hasConcept C2779786085 @default.
• W4294307521 hasConcept C2908647359 @default.
• W4294307521 hasConcept C530470458 @default.
• W4294307521 hasConcept C71924100 @default.
• W4294307521 hasConcept C72563966 @default.
• W4294307521 hasConcept C86803240 @default.
• W4294307521 hasConcept C99454951 @default.
• W4294307521 hasConceptScore W4294307521C121608353 @default.
• W4294307521 hasConceptScore W4294307521C126322002 @default.
• W4294307521 hasConceptScore W4294307521C143998085 @default.
• W4294307521 hasConceptScore W4294307521C146357865 @default.
• W4294307521 hasConceptScore W4294307521C151730666 @default.
• W4294307521 hasConceptScore W4294307521C201903717 @default.
• W4294307521 hasConceptScore W4294307521C2778292576 @default.
• W4294307521 hasConceptScore W4294307521C2779134260 @default.
• W4294307521 hasConceptScore W4294307521C2779786085 @default.
• W4294307521 hasConceptScore W4294307521C2908647359 @default.
• W4294307521 hasConceptScore W4294307521C530470458 @default.
• W4294307521 hasConceptScore W4294307521C71924100 @default.
• W4294307521 hasConceptScore W4294307521C72563966 @default.
• W4294307521 hasConceptScore W4294307521C86803240 @default.
• W4294307521 hasConceptScore W4294307521C99454951 @default.
• W4294307521 hasIssue "8" @default.
• W4294307521 hasLocation W42943075211 @default.
• W4294307521 hasLocation W42943075212 @default.
• W4294307521 hasOpenAccess W4294307521 @default.
• W4294307521 hasPrimaryLocation W42943075211 @default.
• W4294307521 hasRelatedWork W111573635 @default.
• W4294307521 hasRelatedWork W1722328147 @default.
• W4294307521 hasRelatedWork W2013223170 @default.
• W4294307521 hasRelatedWork W2066747782 @default.
• W4294307521 hasRelatedWork W2593475799 @default.
• W4294307521 hasRelatedWork W2934076975 @default.
• W4294307521 hasRelatedWork W2984545096 @default.
• W4294307521 hasRelatedWork W4322772378 @default.
• W4294307521 hasRelatedWork W812572266 @default.
• W4294307521 hasRelatedWork W2342209702 @default.
• W4294307521 hasVolume "22" @default.
• W4294307521 isParatext "false" @default.
• W4294307521 isRetracted "false" @default.
• W4294307521 workType "article" @default.